jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics Inc (NQ: UNCY )

0.4899 -0.0451 (-8.43%)
Streaming Delayed Price Updated: 11:54 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Unicycive Therapeutics Inc

< Previous 1 2 Next >
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Unicycive: The Company Developing Key Kidney Therapies
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. 
Via TheNewswire.com
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
Appointment adds decades of drug development experience from a seasoned executive 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Via ACCESSWIRE
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Via ACCESSWIRE
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®
Via ACCESSWIRE
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
Data highlights the potential safety and reno-protective effect of UNI-494 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug
Via Investor Brand Network
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
By Julian Richard, Benzinga 
Via TheNewswire.com
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
By Julian Richard, Benzinga 
Via TheNewswire.com
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Unicycive to Participate in Upcoming Investor Conferences
Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News